3rd patient death potentially tied to Eisai's Alzheimer's drug reported

A third patient death potentially tied to Eisai and Biogen’s Alzheimer’s disease drug lecanemab has been reported in a phase 3 extension study, according to a report from Science.

The latest death was attributed to brain swelling and bleeding, as well as seizures. The patient was a 79-year-old Florida woman who was participating in the extension portion of the phase 3 trial, according to Science.